No quarterly revenue total was found in ANNEXON, INC.'s SEC filings.
Annexon, Inc. (ANNX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$48.1 million. As of Jun 30, 2026 it held $209.2 million in cash and investments and $24.7 million in total debt.
Revenue
—
Net income
$-55.35M
-12.6% vs year-ago quarter
Operating cash flow
$-48.01M
-26.1% vs year-ago quarter
Free cash flow
$-48.14M
-26.4% vs year-ago quarter
EPS
$-0.28
+17.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
149.36M
+36.6% vs year-ago quarter
Net cash
$184.59M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANNX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1528115
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$57.2M | -$46.1M | -$50.3M | -$57.0M | -$51.7M |
| Net income | -$55.3M | -$44.1M | -$48.3M | -$54.9M | -$49.2M |
| Diluted EPS | -$0.28 | -$0.23 | -$0.28 | -$0.37 | -$0.34 |
| Operating cash flow | -$48.0M | -$46.8M | -$45.9M | -$52.3M | -$38.1M |
| Free cash flow | -$48.1M | -$46.8M | -$45.9M | -$52.4M | -$38.1M |
| Total assets | $246.1M | $262.9M | $277.6M | $229.1M | $264.6M |
| Total liabilities | $60.0M | $58.4M | $65.9M | $67.7M | $65.6M |
| Stockholders' equity | $186.1M | $204.5M | $211.6M | $161.4M | $199.0M |
| Cash and investments | $209.2M | $225.0M | $238.3M | $188.7M | $227.0M |
| Total debt | $24.7M | $25.4M | $26.2M | $26.9M | $27.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
All 522 Annexon, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.